Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data - Top-Institutions - DentalSpire

Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data

  • By

  • Ying-Kui Jiang

  • Wen-Jia Qiu

  • Yun Cao

  • Jun-Tian Huang

  • Rong-Sheng Zhu

  • Ling-Hong Zhou

  • Hua-Zhen Zhao

  • Jie Tong

  • Zhong-Qing Chen

  • Li-Ping Zhu

  • February 10, 2026

  • 0 min

Share

Top Institutions in Dental

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Medical Mycology
    • Clinical Pharmacology

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Medical Mycology
    • Transplant Infectious Diseases

  • #3

    All India Institute of Medical Sciences (AIIMS)
    All India Institute of Medical Sciences (AIIMS)

    New Delhi, N/A

    Key Differentiators

    • Infectious Diseases
    • Medical Mycology
    • Public Health

  • #4

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Medical Mycology
    • Immunology

  • #5

    Peking University Health Science Center
    Peking University Health Science Center

    Beijing, N/A

    Key Differentiators

    • Infectious Diseases
    • Medical Mycology
    • Pharmacology

Original Source(s)

Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data

  • by Ying-Kui Jiang, Wen-Jia Qiu, Yun Cao, Jun-Tian Huang, Rong-Sheng Zhu, Ling-Hong Zhou, Hua-Zhen Zhao, Jie Tong, Zhong-Qing Chen, Li-Ping Zhu

  • February 10, 2026

Related Content

Recommendations for estimating and reporting vaccine effectiveness by time since vaccination: a COVID-19 case study

Cardiovascular disease prevention and management in COVID-19: a clinical consensus statement of the European Association of Preventive Cardiology, the European Association of Cardiovascular Imaging, the Association of Cardiovascular Nursing & Allied Professions, the European Association of Percutaneous Cardiovascular Interventions, and the Heart Failure Association of the ESC

Viral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies